EXCERPT
Proteolysis-targeting chimera (PROTAC) molecules overcome a once-insurmountable drug development challenge. For years, researchers have known some proteins are implicated in human disease but have been unable to identify defined binding sites to unlock their therapeutic potential. An estimated 85% of the proteome is considered “undruggable”
PROTACs offer a way to target such “undruggable” proteins and improve patient outcomes, creating a need for teams with the synthesis and purification capabilities to support development of the molecules. Piramal Pharma Solutions is well versed in the synthesis and purification techniques needed to accelerate PROTAC R&D programs. Read this whitepaper to learn more how Piramal can partner with you to help accelerate your PROTAC development program and address unmet needs
